Telmisartan

替米沙坦

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameTelmisartan
Drug Alias NameTelmisartanum替咪沙坦KinzalTelma美卡素 +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Risk Reduction BehaviorDrug-Related Side Effects and Adverse Reactions +[19] 
Global Approved IndicationsRisk Reduction BehaviorHypertensionMyocardial Infarction +[4] 
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1998/11/10
Country/TerritoryCzechiaCanadaUnited States +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim Pharma Gmbh & Co KgTanta University +[7] 
Inactive CompaniesLudwig Maximilians University Of MunichYale UniversityHeidelberg University +[10] 
Active IndicationsRisk Reduction BehaviorHypertensionMyocardial Infarction +[7] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsObesity +[12] 

Other Information

ATC CodeC09CA07
Related LinksWikipediaDrugBankKEGG